Philogen (PHIL) Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
PHIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €20.70 |
| 52 Week High | €27.80 |
| 52 Week Low | €19.56 |
| Beta | 0.0077 |
| 1 Month Change | -7.17% |
| 3 Month Change | -4.17% |
| 1 Year Change | 0% |
| 3 Year Change | 33.98% |
| 5 Year Change | 29.38% |
| Change since IPO | 24.03% |
Recent News & Updates
Recent updates
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Oct 04
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Apr 14Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Mar 31What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
Feb 24Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
Jun 03Shareholder Returns
| PHIL | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -2.6% | 2.3% | 3.4% |
| 1Y | 0% | 34.5% | 31.7% |
Return vs Industry: PHIL underperformed the Italian Biotechs industry which returned 34.5% over the past year.
Return vs Market: PHIL underperformed the Italian Market which returned 31.7% over the past year.
Price Volatility
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IT Market | 8.0% |
| 10% least volatile stocks in IT Market | 3.0% |
Stable Share Price: PHIL has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: PHIL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 201 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer. It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors.
Philogen S.p.A. Fundamentals Summary
| PHIL fundamental statistics | |
|---|---|
| Market cap | €833.82m |
| Earnings (TTM) | €229.68m |
| Revenue (TTM) | €319.73m |
Is PHIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIL income statement (TTM) | |
|---|---|
| Revenue | €319.73m |
| Cost of Revenue | €39.57m |
| Gross Profit | €280.16m |
| Other Expenses | €50.49m |
| Earnings | €229.68m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 12, 2026
| Earnings per share (EPS) | 5.70 |
| Gross Margin | 87.62% |
| Net Profit Margin | 71.83% |
| Debt/Equity Ratio | 0.01% |
How did PHIL perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 23:35 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Philogen S.p.A. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |